NASDAQLXEO - Smart Spend Central

Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy – Slideshow (NASDAQ:LXEO) 2026-01-13

By wpadminJanuary 13, 2026

This article was written byFollowSeeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings…

What's Hot

Funding approved to reduce cold deaths

$3.82 w/ Sub & Save

Satisfy Your Cravings with These 17 Guilt-Free Healthy Junk Food

Browsing: NASDAQLXEO

Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy – Slideshow (NASDAQ:LXEO) 2026-01-13

Funding approved to reduce cold deaths

$3.82 w/ Sub & Save

Satisfy Your Cravings with These 17 Guilt-Free Healthy Junk Food

Funding approved to reduce cold deaths

$3.82 w/ Sub & Save

Satisfy Your Cravings with These 17 Guilt-Free Healthy Junk Food

Funding approved to reduce cold deaths

$3.82 w/ Sub & Save

Satisfy Your Cravings with These 17 Guilt-Free Healthy Junk Food

Subway Making Negative Changes To Loyalty Program